经导管主动脉瓣置换术对慢性肾脏病分期的影响
本研究基于PARTNER 1、2及PARTNER 2 S3试验中5190例接受TAVR的重度主动脉瓣狭窄患者,评估术后慢性肾脏病(CKD)分期的变化及相关因素。结果显示多数患者CKD分期不变或改善,仅极少数进展至终末期,且术后eGFR与中期生存相关。
要点
- TAVR后多数患者CKD分期稳定或改善,进展至CKD 5期罕见。
- 术前eGFR较高和经股动脉入路与术后eGFR较高相关。
- 术后eGFR较低与中期生存率降低相关。
核心结论
- 重度主动脉瓣狭窄患者接受TAVR后,即使基线eGFR受损,CKD分期更可能保持不变或改善而非恶化。
- 主动脉瓣狭窄可能参与心肾综合征,TAVR可使其改善。
研究设计与样本
- 评估术前及 procedural 变量与术后eGFR、术后7天内CKD分期变化及术后eGFR与中期死亡率的关系。
主要发现
- 基线时91%的患者存在CKD分期≥2。
- TAVR后多数患者CKD分期改善或不变:1期77%、2期90%、3A期89%、3B期94%、4期99%。
- 术后7天内进展至CKD 5期的比例极低(1/2892,0.035%)。
- 3546例数据可用的患者中,70例(2.0%)接受了术后透析。
- 术前eGFR较高和经股动脉入路与术后eGFR较高强相关;较低基线及纵向术后eGFR与较低中期生存率相关。
临床怎么用
- 对于重度主动脉瓣狭窄合并慢性肾脏病患者,TAVR后肾功能多稳定或改善,不应因基线肾功能不全而排除TAVR。
- 术前eGFR较高和经股动脉入路可能有利于术后肾功能,临床决策时可考虑。
- 术后eGFR下降与中期死亡风险增加相关,需加强术后肾功能监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effect of transcatheter aortic valve replacement (TAVR) on kidney function stage in patients with aortic stenosis remains poorly understood. We hypothesized that in some patients, TAVR results in improved kidney function by alleviating cardiorenal syndrome. OBJECTIVES: The purpose of this study was to assess change in chronic kidney disease (CKD) stage following TAVR, identify variables associated with pre- and post-TAVR estimated glomerular filtration rate (eGFR), and assess association of post-TAVR eGFR with mortality. METHODS: Patients (n = 5,190) receiving TAVR in the PARTNER (Placement of Aortic Transcatheter Valves) 1, 2, and PARTNER 2 S3 trials between April 2007 and October 2014 were included. Pre-TAVR and procedural variables associated with post-TAVR eGFR, change in CKD stage at ≤7 days post-TAVR, and association of post-TAVR eGFR on intermediate-term mortality were assessed. RESULTS: At baseline, CKD stage ≥2 was present in 91% of patients. CKD stage either improved or was unchanged following TAVR in the majority of patients (77% stage 1, 90% stage 2, 89% stage 3A, 94% stage 3B, and 99% stage 4). Progression to CKD stage 5 occurred in 1 (0.035%) of 2,892 patients within 7 days post-TAVR. Of 3,546 patients in whom data were available, 70 (2.0%) underwent post-TAVR dialysis. Higher pre-TAVR eGFR and transfemoral approach were strongly associated with higher post-TAVR eGFR. Lower baseline and longitudinal post-TAVR eGFR were associated with lower intermediate-term survival. CONCLUSIONS: In patients with severe aortic stenosis undergoing TAVR, even with baseline impaired eGFR, CKD stage is more likely to stay the same or improve than worsen. Aortic stenosis may contribute to cardiorenal syndrome that improves with TAVR.
引用
- Cubeddu RJ, Asher CR, Lowry AM, et al. Impact of Transcatheter Aortic Valve Replacement on Severity of Chronic Kidney Disease. J Am Coll Cardiol. 2020. PMID: 32943158. doi:10.1016/j.jacc.2020.07.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。